title: Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
abstract: Few studies focused on the effects of cabergoline on sleep-wake cycle in PD. Twelve patients affected by PD treated with levodopa as monotherapy underwent two 24-hour ambulatory polysomnographic (A-PSG) sessions twice: in baseline condition (levodopa as monotherapy) and after addition of cabergoline. In each condition, a subjective evaluation of sleep quality and daytime sleepiness was obtained by means of Parkinson's disease Sleep Scale (PDSS) and the Epworth Sleepiness Scale. The statistical analysis of sleep parameters revealed a significant increase of sleep efficiency and slow wave sleep under cabergoline. The PDSS total score showed a significant improvement of overall sleep quality after cabergoline. No significant changes in daytime sleepiness were observed. No patient referred and/or showed sleep attacks before and after addition of cabergoline. We hypothesize that the long-lasting effect of cabergoline may improve the objective quality of nocturnal sleep in PD patients complaining nocturnal motor disability without inducing daytime sleepiness.
authors.affiliation: University of Rome Tor Vergata Policlinico Tor Vergata Servizio di Neurofisiopatologia Centro di Medicina del Sonno, Rome, Italy. a_romigi@inwind.it
authors.forename: A
authors.initials: A
authors.lastname: Romigi
authors.forename: P
authors.initials: P
authors.lastname: Stanzione
authors.forename: M G
authors.initials: MG
authors.lastname: Marciani
authors.forename: F
authors.initials: F
authors.lastname: Izzi
authors.forename: F
authors.initials: F
authors.lastname: Placidi
authors.forename: A
authors.initials: A
authors.lastname: Cervellino
authors.forename: P
authors.initials: P
authors.lastname: Giacomini
authors.forename: L
authors.initials: L
authors.lastname: Brusa
authors.forename: K
authors.initials: K
authors.lastname: Grossi
authors.forename: M
authors.initials: M
authors.lastname: Pierantozzi
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077465:Cabergoline; D002940:Circadian Rhythm; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D017286:Polysomnography; D012890:Sleep / Q000187:drug effects*; D014851:Wakefulness / Q000187:drug effects*
chemical_list: D000978:Antiparkinson Agents; D004873:Ergolines; D007980:Levodopa; D000077465:Cabergoline